Company profile

Seagen

Privately held: no public share price

Assets

(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 3 of 3 assets
Target & Modality
Brentuximab Vedotin
Phase 3
Anti-CD30 antibody-drug conjugateAntibody–drug conjugate
Non-Small Cell Lung Cancer
Tisotumab Vedotin Humax-tf-adc
Phase 3
Tissue Factor (TF)Antibody–drug conjugate
Non-Small Cell Lung Cancer
Sea-tgt
Phase 1
TIGITMonoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.